Compare GL & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GL | BMRN |
|---|---|---|
| Founded | 1900 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3B | 10.0B |
| IPO Year | N/A | 1999 |
| Metric | GL | BMRN |
|---|---|---|
| Price | $140.09 | $59.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 19 |
| Target Price | ★ $160.00 | $89.74 |
| AVG Volume (30 Days) | 489.6K | ★ 3.0M |
| Earning Date | 02-04-2026 | 02-18-2026 |
| Dividend Yield | ★ 0.77% | N/A |
| EPS Growth | 16.72 | ★ 59.53 |
| EPS | ★ 13.77 | 2.68 |
| Revenue | ★ $5,940,974,000.00 | $3,094,001,000.00 |
| Revenue This Year | $7.48 | $13.35 |
| Revenue Next Year | $5.31 | $9.06 |
| P/E Ratio | ★ $10.15 | $22.17 |
| Revenue Growth | 3.73 | ★ 12.39 |
| 52 Week Low | $109.38 | $50.76 |
| 52 Week High | $147.83 | $73.51 |
| Indicator | GL | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 52.37 | 59.45 |
| Support Level | $140.58 | $58.44 |
| Resistance Level | $144.44 | $60.58 |
| Average True Range (ATR) | 2.32 | 1.94 |
| MACD | -0.12 | 0.37 |
| Stochastic Oscillator | 22.15 | 62.78 |
Globe Life Inc is an insurance holding company. It provides a variety of life and supplemental health insurance products and annuities to a broad base of customers. The company's core operations are organized into three reportable segments: life insurance, supplemental health insurance and investments. Investment activities, conducted by the investment segment, focus on seeking investments with a yield and term appropriate to support the insurance product obligations. These investments generally consist of fixed maturities and, over the long term, the expected yields are considered when setting insurance premium rates and product profitability expectations.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.